2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases

Chern En Chiang, Shih Yi Lin, Tsung Hsien Lin, Tzung Dau Wang, Hung I. Yeh, Jung Fu Chen, Chia Ti Tsai, Yi Jen Hung, Yi Heng Li, Ping Yen Liu, Kuan Cheng Chang, Kang Ling Wang, Ting Hsing Chao, Kou Gi Shyu, Wei Shiung Yang, Kwo Chang Ueng, Pao Hsien Chu, Wei Hsian Yin, Yen Wen Wu, Hao Min Cheng & 7 others Shyi Jang Shin, Chien Ning Huang, Lee Ming Chuang, Shing Jong Lin, San Jou Yeh, Wayne Huey Herng Sheu, Jiunn Lee Lin

Research output: Contribution to journalArticle

  • 1 Citations

Abstract

The global incidence and prevalence of type 2 diabetes have been escalating in recent decades. Patients with type 2 diabetes have an increased risk of atherosclerotic cardiovascular disease (ASCVD). About two-thirds of death in type 2 diabetes are due to ASCVD, including 40% from coronary heart disease (CHD), 15% from heart failure (HF), and 10% from stroke. The association between hyperglycemia and elevated CV risk has been demonstrated in multiple cohort studies. However, clinical trials of intensive glucose reduction did not significantly reduce macrovascular outcomes. It remains unclear whether the absence of demonstrable benefits is attributed to the inclusion of patients with far advanced ASCVD in whom a short treatment period is barely enough for CV protective effects to be shown, or complications associated with the treatment such as hypoglycemia hamper the beneficial effects to manifest, or simply glucose-lowering per se is ineffective. Since the US FDA issued a mandate in December 2008 that every new anti-diabetic agent requires rigorous assessments of its CV safety, there have been more than 200,000 patients enrolled in a number of randomized controlled trials (RCTs), and around half of them have been completed and published. The results of these CV outcome trials are important for clinicians in their clinical practice, and also provide an opportunity for academic society to formulate treatment guidelines or consensus to provide specific recommendations for glucose control in various CV diseases. The Taiwan Society of Cardiology (TSOC) and the Diabetes Association of Republic of China (DAROC), aiming to formulate a treatment consensus in type 2 diabetic patients with CVD, have appointed a jointed consensus group for the 2018 Consensus of TSOC/DAROC (Taiwan) on the Pharmacological Management of Patients with Type 2 Diabetes and CV Diseases. The consensus is comprised of 5 major parts: 1) Treatment of diabetes in patients with hypertension, 2) Treatment of diabetes in patients with CHD, 3) Treatment of diabetes in patients with stage 3 chronic kidney disease, 4) Treatment of diabetes in patients with a history of stroke, and 5) Treatment of diabetes in patients with HF. The members of the consensus group comprehensively reviewed all the evidence, mainly RCTs, and also included meta-analyses, cohort studies, and studies using claim data. The treatment targets of HbA1c were provided. The anti-diabetic agents were ranked according to their clinical evidence. The consensus is not mandatory. The final decision may need to be individualized and based on clinicians’ discretion.

LanguageEnglish
Pages189-222
Number of pages34
JournalJournal of the Chinese Medical Association
Volume81
Issue number3
DOIs
Publication statusPublished - Mar 1 2018
Externally publishedYes

Fingerprint

Cardiology
Taiwan
Type 2 Diabetes Mellitus
Cardiovascular Diseases
Pharmacology
Therapeutics
Glucose
Coronary Disease
Cohort Studies
Randomized Controlled Trials
Heart Failure
Stroke
Chronic Renal Insufficiency
Hypoglycemia
Hyperglycemia
Meta-Analysis
Clinical Trials
Guidelines
Hypertension
Safety

Keywords

  • Anti-diabetic agents
  • Chronic kidney disease
  • Coronary heart disease
  • Heart failure
  • Hypertension
  • Stroke
  • Type 2 diabetes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. / Chiang, Chern En; Lin, Shih Yi; Lin, Tsung Hsien; Wang, Tzung Dau; Yeh, Hung I.; Chen, Jung Fu; Tsai, Chia Ti; Hung, Yi Jen; Li, Yi Heng; Liu, Ping Yen; Chang, Kuan Cheng; Wang, Kang Ling; Chao, Ting Hsing; Shyu, Kou Gi; Yang, Wei Shiung; Ueng, Kwo Chang; Chu, Pao Hsien; Yin, Wei Hsian; Wu, Yen Wen; Cheng, Hao Min; Shin, Shyi Jang; Huang, Chien Ning; Chuang, Lee Ming; Lin, Shing Jong; Yeh, San Jou; Sheu, Wayne Huey Herng; Lin, Jiunn Lee.

In: Journal of the Chinese Medical Association, Vol. 81, No. 3, 01.03.2018, p. 189-222.

Research output: Contribution to journalArticle

Chiang, CE, Lin, SY, Lin, TH, Wang, TD, Yeh, HI, Chen, JF, Tsai, CT, Hung, YJ, Li, YH, Liu, PY, Chang, KC, Wang, KL, Chao, TH, Shyu, KG, Yang, WS, Ueng, KC, Chu, PH, Yin, WH, Wu, YW, Cheng, HM, Shin, SJ, Huang, CN, Chuang, LM, Lin, SJ, Yeh, SJ, Sheu, WHH & Lin, JL 2018, '2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases' Journal of the Chinese Medical Association, vol. 81, no. 3, pp. 189-222. https://doi.org/10.1016/j.jcma.2018.01.001
Chiang, Chern En ; Lin, Shih Yi ; Lin, Tsung Hsien ; Wang, Tzung Dau ; Yeh, Hung I. ; Chen, Jung Fu ; Tsai, Chia Ti ; Hung, Yi Jen ; Li, Yi Heng ; Liu, Ping Yen ; Chang, Kuan Cheng ; Wang, Kang Ling ; Chao, Ting Hsing ; Shyu, Kou Gi ; Yang, Wei Shiung ; Ueng, Kwo Chang ; Chu, Pao Hsien ; Yin, Wei Hsian ; Wu, Yen Wen ; Cheng, Hao Min ; Shin, Shyi Jang ; Huang, Chien Ning ; Chuang, Lee Ming ; Lin, Shing Jong ; Yeh, San Jou ; Sheu, Wayne Huey Herng ; Lin, Jiunn Lee. / 2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. In: Journal of the Chinese Medical Association. 2018 ; Vol. 81, No. 3. pp. 189-222.
@article{a5d95a3fdaad489d89672ceaf670278e,
title = "2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases",
abstract = "The global incidence and prevalence of type 2 diabetes have been escalating in recent decades. Patients with type 2 diabetes have an increased risk of atherosclerotic cardiovascular disease (ASCVD). About two-thirds of death in type 2 diabetes are due to ASCVD, including 40{\%} from coronary heart disease (CHD), 15{\%} from heart failure (HF), and 10{\%} from stroke. The association between hyperglycemia and elevated CV risk has been demonstrated in multiple cohort studies. However, clinical trials of intensive glucose reduction did not significantly reduce macrovascular outcomes. It remains unclear whether the absence of demonstrable benefits is attributed to the inclusion of patients with far advanced ASCVD in whom a short treatment period is barely enough for CV protective effects to be shown, or complications associated with the treatment such as hypoglycemia hamper the beneficial effects to manifest, or simply glucose-lowering per se is ineffective. Since the US FDA issued a mandate in December 2008 that every new anti-diabetic agent requires rigorous assessments of its CV safety, there have been more than 200,000 patients enrolled in a number of randomized controlled trials (RCTs), and around half of them have been completed and published. The results of these CV outcome trials are important for clinicians in their clinical practice, and also provide an opportunity for academic society to formulate treatment guidelines or consensus to provide specific recommendations for glucose control in various CV diseases. The Taiwan Society of Cardiology (TSOC) and the Diabetes Association of Republic of China (DAROC), aiming to formulate a treatment consensus in type 2 diabetic patients with CVD, have appointed a jointed consensus group for the 2018 Consensus of TSOC/DAROC (Taiwan) on the Pharmacological Management of Patients with Type 2 Diabetes and CV Diseases. The consensus is comprised of 5 major parts: 1) Treatment of diabetes in patients with hypertension, 2) Treatment of diabetes in patients with CHD, 3) Treatment of diabetes in patients with stage 3 chronic kidney disease, 4) Treatment of diabetes in patients with a history of stroke, and 5) Treatment of diabetes in patients with HF. The members of the consensus group comprehensively reviewed all the evidence, mainly RCTs, and also included meta-analyses, cohort studies, and studies using claim data. The treatment targets of HbA1c were provided. The anti-diabetic agents were ranked according to their clinical evidence. The consensus is not mandatory. The final decision may need to be individualized and based on clinicians’ discretion.",
keywords = "Anti-diabetic agents, Chronic kidney disease, Coronary heart disease, Heart failure, Hypertension, Stroke, Type 2 diabetes",
author = "Chiang, {Chern En} and Lin, {Shih Yi} and Lin, {Tsung Hsien} and Wang, {Tzung Dau} and Yeh, {Hung I.} and Chen, {Jung Fu} and Tsai, {Chia Ti} and Hung, {Yi Jen} and Li, {Yi Heng} and Liu, {Ping Yen} and Chang, {Kuan Cheng} and Wang, {Kang Ling} and Chao, {Ting Hsing} and Shyu, {Kou Gi} and Yang, {Wei Shiung} and Ueng, {Kwo Chang} and Chu, {Pao Hsien} and Yin, {Wei Hsian} and Wu, {Yen Wen} and Cheng, {Hao Min} and Shin, {Shyi Jang} and Huang, {Chien Ning} and Chuang, {Lee Ming} and Lin, {Shing Jong} and Yeh, {San Jou} and Sheu, {Wayne Huey Herng} and Lin, {Jiunn Lee}",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.jcma.2018.01.001",
language = "English",
volume = "81",
pages = "189--222",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "3",

}

TY - JOUR

T1 - 2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases

AU - Chiang, Chern En

AU - Lin, Shih Yi

AU - Lin, Tsung Hsien

AU - Wang, Tzung Dau

AU - Yeh, Hung I.

AU - Chen, Jung Fu

AU - Tsai, Chia Ti

AU - Hung, Yi Jen

AU - Li, Yi Heng

AU - Liu, Ping Yen

AU - Chang, Kuan Cheng

AU - Wang, Kang Ling

AU - Chao, Ting Hsing

AU - Shyu, Kou Gi

AU - Yang, Wei Shiung

AU - Ueng, Kwo Chang

AU - Chu, Pao Hsien

AU - Yin, Wei Hsian

AU - Wu, Yen Wen

AU - Cheng, Hao Min

AU - Shin, Shyi Jang

AU - Huang, Chien Ning

AU - Chuang, Lee Ming

AU - Lin, Shing Jong

AU - Yeh, San Jou

AU - Sheu, Wayne Huey Herng

AU - Lin, Jiunn Lee

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The global incidence and prevalence of type 2 diabetes have been escalating in recent decades. Patients with type 2 diabetes have an increased risk of atherosclerotic cardiovascular disease (ASCVD). About two-thirds of death in type 2 diabetes are due to ASCVD, including 40% from coronary heart disease (CHD), 15% from heart failure (HF), and 10% from stroke. The association between hyperglycemia and elevated CV risk has been demonstrated in multiple cohort studies. However, clinical trials of intensive glucose reduction did not significantly reduce macrovascular outcomes. It remains unclear whether the absence of demonstrable benefits is attributed to the inclusion of patients with far advanced ASCVD in whom a short treatment period is barely enough for CV protective effects to be shown, or complications associated with the treatment such as hypoglycemia hamper the beneficial effects to manifest, or simply glucose-lowering per se is ineffective. Since the US FDA issued a mandate in December 2008 that every new anti-diabetic agent requires rigorous assessments of its CV safety, there have been more than 200,000 patients enrolled in a number of randomized controlled trials (RCTs), and around half of them have been completed and published. The results of these CV outcome trials are important for clinicians in their clinical practice, and also provide an opportunity for academic society to formulate treatment guidelines or consensus to provide specific recommendations for glucose control in various CV diseases. The Taiwan Society of Cardiology (TSOC) and the Diabetes Association of Republic of China (DAROC), aiming to formulate a treatment consensus in type 2 diabetic patients with CVD, have appointed a jointed consensus group for the 2018 Consensus of TSOC/DAROC (Taiwan) on the Pharmacological Management of Patients with Type 2 Diabetes and CV Diseases. The consensus is comprised of 5 major parts: 1) Treatment of diabetes in patients with hypertension, 2) Treatment of diabetes in patients with CHD, 3) Treatment of diabetes in patients with stage 3 chronic kidney disease, 4) Treatment of diabetes in patients with a history of stroke, and 5) Treatment of diabetes in patients with HF. The members of the consensus group comprehensively reviewed all the evidence, mainly RCTs, and also included meta-analyses, cohort studies, and studies using claim data. The treatment targets of HbA1c were provided. The anti-diabetic agents were ranked according to their clinical evidence. The consensus is not mandatory. The final decision may need to be individualized and based on clinicians’ discretion.

AB - The global incidence and prevalence of type 2 diabetes have been escalating in recent decades. Patients with type 2 diabetes have an increased risk of atherosclerotic cardiovascular disease (ASCVD). About two-thirds of death in type 2 diabetes are due to ASCVD, including 40% from coronary heart disease (CHD), 15% from heart failure (HF), and 10% from stroke. The association between hyperglycemia and elevated CV risk has been demonstrated in multiple cohort studies. However, clinical trials of intensive glucose reduction did not significantly reduce macrovascular outcomes. It remains unclear whether the absence of demonstrable benefits is attributed to the inclusion of patients with far advanced ASCVD in whom a short treatment period is barely enough for CV protective effects to be shown, or complications associated with the treatment such as hypoglycemia hamper the beneficial effects to manifest, or simply glucose-lowering per se is ineffective. Since the US FDA issued a mandate in December 2008 that every new anti-diabetic agent requires rigorous assessments of its CV safety, there have been more than 200,000 patients enrolled in a number of randomized controlled trials (RCTs), and around half of them have been completed and published. The results of these CV outcome trials are important for clinicians in their clinical practice, and also provide an opportunity for academic society to formulate treatment guidelines or consensus to provide specific recommendations for glucose control in various CV diseases. The Taiwan Society of Cardiology (TSOC) and the Diabetes Association of Republic of China (DAROC), aiming to formulate a treatment consensus in type 2 diabetic patients with CVD, have appointed a jointed consensus group for the 2018 Consensus of TSOC/DAROC (Taiwan) on the Pharmacological Management of Patients with Type 2 Diabetes and CV Diseases. The consensus is comprised of 5 major parts: 1) Treatment of diabetes in patients with hypertension, 2) Treatment of diabetes in patients with CHD, 3) Treatment of diabetes in patients with stage 3 chronic kidney disease, 4) Treatment of diabetes in patients with a history of stroke, and 5) Treatment of diabetes in patients with HF. The members of the consensus group comprehensively reviewed all the evidence, mainly RCTs, and also included meta-analyses, cohort studies, and studies using claim data. The treatment targets of HbA1c were provided. The anti-diabetic agents were ranked according to their clinical evidence. The consensus is not mandatory. The final decision may need to be individualized and based on clinicians’ discretion.

KW - Anti-diabetic agents

KW - Chronic kidney disease

KW - Coronary heart disease

KW - Heart failure

KW - Hypertension

KW - Stroke

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85041913940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041913940&partnerID=8YFLogxK

U2 - 10.1016/j.jcma.2018.01.001

DO - 10.1016/j.jcma.2018.01.001

M3 - Article

VL - 81

SP - 189

EP - 222

JO - Journal of the Chinese Medical Association

T2 - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 3

ER -